Compare ARE & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARE | AMRX |
|---|---|---|
| Founded | 1994 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4B | 6.4B |
| IPO Year | 1997 | 2018 |
| Metric | ARE | AMRX |
|---|---|---|
| Price | $44.00 | $21.40 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 7 |
| Target Price | ★ $49.93 | $24.29 |
| AVG Volume (30 Days) | 2.6M | ★ 3.5M |
| Earning Date | 10-26-2026 | 11-03-2026 |
| Dividend Yield | ★ 6.50% | N/A |
| EPS Growth | N/A | ★ 157.89 |
| EPS | N/A | ★ 0.29 |
| Revenue | ★ $3,026,556,000.00 | N/A |
| Revenue This Year | N/A | $6.38 |
| Revenue Next Year | N/A | $9.21 |
| P/E Ratio | ★ N/A | $74.71 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $38.34 | $11.39 |
| 52 Week High | $59.76 | $22.07 |
| Indicator | ARE | AMRX |
|---|---|---|
| Relative Strength Index (RSI) | 48.78 | 59.47 |
| Support Level | $39.23 | $18.90 |
| Resistance Level | $55.20 | N/A |
| Average True Range (ATR) | 1.94 | 0.86 |
| MACD | 0.47 | 0.06 |
| Stochastic Oscillator | 60.23 | 78.85 |
Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle, Texas, and Canada. The Company is a life science real estate investment trust focused on developing, redeveloping, and operating properties that provide space for lease to tenants in the life science industry.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.